Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 46

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Summary

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Diabetes and Hepatitis B.

The latest report Free Fatty Acid Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

- The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
Amgen Inc
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
Hyundai Pharmaceutical Co Ltd
Johnson & Johnson
Merck & Co Inc
Takeda Pharmaceutical Co Ltd
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
AM-1638 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasiglifam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYDG-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
Featured News & Press Releases
Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development
Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes
May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society
Aug 22, 2012: Takeda Launches Phase III Clinical Trial In Asia For TAK-875 To Treat Diabetes
Feb 27, 2012: Takeda Announces Publication Of Phase II Data Of TAK-875 In The Lancet, Demonstrates Improved Glycemic Control In Patients With Type 2 Diabetes
Oct 18, 2011: Takeda Initiates Phase III Clinical Trial Program In US, Latin America, And Europe For Investigational Type 2 Diabetes Therapy TAK-875
Sep 12, 2011: Takeda's TAK-875 Enters Into Phase III Clinical Trials For Treatment Of Type 2 Diabetes In Japan
Jun 28, 2011: Takeda Presents Late Breaking Data Of TAK-875 At American Diabetes Association 71st Annual Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Cadila Healthcare Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • Global Zinc Lactate Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Zinc lactate is a zinc salt of lactic acid and commonly used ingredient in toothpaste, mouthwash, chewing gums and other oral hygiene products. Scope of the Report: The demand for zinc lactate has been steadily increasing on the backdrop of increasing health concerns across the globe. The worldwide market for Zinc Lactate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to......
  • Global Tetanus Toxoid Vaccine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. Scope of the Report: US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The worldwide market for Tetanus Toxoid Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. ......
  • Global Mental Illness Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Mental Illness is a psychological anomaly that is reflected in patient's behavior through disability, distress, or any conduct that is not considered as normal mental development. The causes of mental lllness are very diverse and often unclear in most cases. Scope of the Report: The worldwide market for Mental Illness Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a ne......
  • Global Ovarian Cancer Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. Scope of the Report: The worldwide market for Ovarian Cancer Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Ovarian Cancer Treatmen......
  • Global Pain and Fever Relief Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 120
    The demand for Pain and Fever Relief Drugs will continue to grow in the next few years. Scope of the Report: The worldwide market for Pain and Fever Relief Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Pain and Fever Relief Drugs in global market, especially in North America, Europe and Asia-Pac......
  • Global Pediatric Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 137
    The market for pediatric pharmaceuticals has become an increasingly important tool in life-cycle management. However, line extensions using children's formulations to increase patent life of existing adult dose drugs are only one of the drivers of this large, but little-studied market. Scope of the Report: The worldwide market for Pediatric Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in ......
  • Global Pneumonia Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing. A variety of organisms, including bacteria, viruses and fungi, can cause pneumonia. Scope of the Report: The worldwide market for Pneumonia Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from ......
  • Global Prostate Cancer Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 117
    Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Scope of the Report: The worldwide market for Prostate Cancer Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Prostate Cancer Treatment ......
  • Global Tuberculosis Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 122
    Tuberculosis (TB) is a disease caused by bacteria called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. Scope of the Report: The worldwide market for Tuberculosis Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs